Genzyme
Executive Summary
Cambridge, Mass.-based company's gene therapy for cystic fibrosis receives orphan drug status from FDA, Genzyme announces July 7. In January, Genzyme's recombinant cystic fibrosis transmembrane conductance regulator also gained orphan designation.